Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

British Columbia to be first Canadian province to switch patients to biosimilars

The Canadian province of British Columbia said its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars.

Read More »

Novartis shares rise after lifting 2019 profit outlook

Novartis raised the company’s 2019 profit target, striking an upbeat tone over a legal fight with peer and partner Amgen and on the safety of a key gene therapy that could win approval in May 2019.

Read More »

Lilly’s Taltz Shows Promise in Spondyloarthritis Trial

Eli Lilly announced results from the COAST-X Phase III study of Taltz in non-radiographic axial spondyloarthritis in patients who had no previous disease-modifying anti-rheumatic drug treatment.

Read More »

High Dose of Pfizer’s Xeljanz Raises Red Flag in a Post-Marketing Study

Pfizer’s blockbuster rheumatoid arthritis drug Xeljanz has been a strong performer for the company, bringing in $1.77 billion in revenue last year, but now the company has indicated it intends to make a change in a post-marketing study due to safety concerns.

Read More »

Top 10 Pipelines To Watch: 2019 Annual Report

The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.

Read More »

Celgene Q4 2018 profit beats forecast

Celgene Corp. – which is being bought by Bristol-Myers Squibb Co. – reported a better-than-expected fourth-quarter 2018 profit, driven mainly by higher sales of the psoriasis drug Otezla.

Read More »

Novartis 2019 growth outlook leaves investors wanting more

Novartis’ 2019 sales and profit guidance disappointed investors seeking more growth from the Swiss drugmaker.

Read More »

J&J fourth-quarter 2018 sales beat expectations

Johnson & Johnson reported better-than-expected fourth-quarter revenue, helped by strong demand for the company’s drugs to treat cancer and psoriasis.

Read More »

Novartis Moves CSU Drug into Phase III After It Outperforms Company’s Own Product

Novartis is taking a treatment for persistent hives into Phase III trials after a mid-stage trial showed that the medication, ligelizumab (QGE031), outperformed Xolair in patients with chronic spontaneous urticaria (CSU) patients whose symptoms are inadequately controlled by H1-antihistamines.

Read More »

Sanofi and Regeneron’s Dupixent gets more positive feedback from U.S. FDA

The U.S. Food and Drug Administration accepted for priority review the license application for the use of Dupixent in adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom